Vera Therapeutics' Upcoming Investor Conferences
Vera Therapeutics, Inc. (NASDAQ: VERA) is preparing to engage with investors through presentations and one-on-one meetings at important investor conferences. This late clinical-stage biotechnology company is dedicated to developing transformative treatments for serious immunological diseases. These conferences offer an excellent opportunity for Vera Therapeutics to connect with potential investors and demonstrate its commitment to advancing healthcare solutions.
Conference Details
Vera Therapeutics will participate in the following major conferences:
8th Annual Evercore Healthcare Conference
This conference will include a fireside chat format, allowing for deep discussions about the company’s innovative therapies. The webcast can be accessed at Evercore Conference Webcast. The event is scheduled for December 2, 2025, at 8:45 AM ET, taking place in Coral Gables, FL.
Citi 2025 Global Healthcare Conference
Another important opportunity is the Citi 2025 Global Healthcare Conference, where Vera will again engage with investors in a fireside chat. Details for this event can be found at Citi Conference Webcast. It will occur on December 3, 2025, at 4:00 PM ET in Miami, FL.
Accessing the Webcasts
For those unable to attend, there will be replay options for both webcasts available for 90 days post-event. Investors and interested parties are encouraged to check out Vera Therapeutics’ investor calendar for more insights into the company’s commitments and future presentations.
About Vera Therapeutics
Vera Therapeutics is focused on developing treatments that specifically address serious immunological diseases. Their lead candidate, atacicept, is a groundbreaking fusion protein designed to be administered at home as a weekly subcutaneous injection. It effectively blocks both BAFF and APRIL, key factors stimulating B cells that produce autoantibodies linked to autoimmune diseases, such as IgA Nephropathy (IgAN) and lupus nephritis.
Beyond IgAN, Vera is exploring additional autoimmune conditions where atacicept may have beneficial effects. The company also possesses an exclusive license for VT-109, a next-generation fusion protein designed with the potential to treat a spectrum of B-cell mediated diseases. Another promising treatment being developed is MAU868, a monoclonal antibody aimed at combating BK virus infections, specifically vital for kidney transplant recipients.
Company's Commitment to Innovation
Vera Therapeutics remains dedicated to advancing cutting-edge treatments to enhance the quality of life for patients suffering from immune-related diseases. Their approach emphasizes the importance of pinpointing the causes of these conditions to redefine the standard of care.
Contact Information
For Investors:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
For Media Inquiries:
Debra Charlesworth
Vera Therapeutics
415-854-8051
corporatecommunications@veratx.com
Frequently Asked Questions
What is Vera Therapeutics?
Vera Therapeutics is a biotechnology firm focusing on innovative treatments for serious immunological diseases.
What is their lead product candidate?
Their primary candidate is atacicept, aimed at treating conditions like IgAN and lupus nephritis.
When are the upcoming investor conferences?
Conferences are on December 2 and 3, 2025, with presentations about the company’s innovative solutions.
How can I access the webcasts?
Webcasts will be available online, with replays accessible for 90 days post-event.
Where can I find more information about Vera Therapeutics?
Visit their official site at www.veratx.com for comprehensive details about their pipeline and corporate initiatives.